Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) announced that Joe Papa, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST. An audio link to the session will be available and kept live for up to 30 days. The company said its presentation slides will be posted on the Investors section of the Emergent website at the time of the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, EBS gained 5.70%, reflecting a notable positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $39M to the company's valuation, bringing the market cap to $729M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Up
Peers showed mixed action: SIGA up 4.23%, KMDA up 0.95% (and in momentum scanner at +5.11%), while others like EOLS and CGC were down. This points to stock-specific rather than broad sector-driven moves around EBS.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | FDA approval update | Positive | -2.6% | FDA cleared Winnipeg facility for raxibacumab drug product manufacturing and testing. |
| Nov 18 | Product milestone | Positive | +0.2% | Marked 10-year NARCAN Nasal Spray approval anniversary and highlighted naloxone access efforts. |
| Nov 12 | Board change | Neutral | -4.5% | Announced retirement of long-serving director Louis W. Sullivan from the board. |
| Oct 29 | Earnings results | Positive | -0.7% | Q3 2025 beat revenue guidance and raised full-year outlook with solid margins. |
| Oct 28 | Survey release | Neutral | -2.3% | Released survey on biological threat concerns and highlighted biodefense capabilities. |
Recent positive operational and earnings headlines have sometimes been followed by negative price reactions, suggesting a pattern of selling into good news.
Over the last few months, Emergent reported multiple milestones, including U.S. FDA approval for raxibacumab manufacturing at its Winnipeg site on Dec 12, 2025 and strong Q3 2025 financials with revenue of $231.1M and net income of $51.2M. Despite these positives and a celebratory 10-year NARCAN® Nasal Spray approval anniversary, several events saw modest to negative price reactions. The current conference appearance follows a phase of operational consolidation, board changes, and public health–focused communications.
Market Pulse Summary
The stock moved +5.7% in the session following this news. A strong positive reaction aligns with the stock’s recent recovery toward its 52-week high of $13.5799 after trading significantly above its 200-day MA of $8.07. However, past events such as FDA approvals and earnings beats sometimes preceded negative or muted moves, indicating a tendency for investors to sell into strength. High prior insider selling activity and past divergences suggest that any sharp upside could face profit-taking pressure.
AI-generated analysis. Not financial advice.
GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST.
The audio link for Emergent’s session may be accessed here and will be live for up to 30 days.
The Company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When will Emergent BioSolutions (EBS) present at the J.P. Morgan Healthcare Conference?
Who will speak for Emergent BioSolutions (EBS) at the January 14, 2026 presentation?
How can investors access the Emergent BioSolutions (EBS) presentation audio from January 14, 2026?
Where will Emergent BioSolutions (EBS) post the presentation slides for the January 14, 2026 session?
Will the Emergent BioSolutions (EBS) J.P. Morgan presentation be available after January 14, 2026?
What time zone is referenced for Emergent BioSolutions (EBS) presentation on January 14, 2026?
